The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Interleukin 1 receptor antagonist. A new member of the interleukin 1 family.
Open accessAbstract
This review has summarized recent information derived from many laboratories on the discovery, characteristics, and properties of a new member of the IL-1 family, IL-1 receptor antagonist. In addition to information, an emphasis has been placed on unanswered questions and new concepts. The existence of this first-described naturally occurring specific cytokine receptor antagonist may lead to a different perspective on the cytokine network. A major unanswered question emphasized throughout this review, that now can be addressed more directly, concerns what are the physiological roles of members of the IL-1 family. Although IL-1 beta is presumed to function primarily as an extracellular cytokine, this molecule lacks a leader peptide, is synthesized and handled by the cells in a manner suggestive of a cytoplasmic (not secretory) protein, and may only be released after cellular injury. Furthermore, although IL-1ra possesses a leader sequence, 50% or more of this protein remains cell associated. Do these observations suggest that members of the IL-1 family possess important intracellular functions, as yet undetermined? IL-1 alpha may play an intracellular role in regulating senescence; an IL-1 alpha antisense oligodeoxynucleotide was shown to prolong the life span of cultured human endothelial cells. Whether intracellular IL-1ra plays a role in influencing life span has not been determined. The discovery of IL-1ra has led to a first level of assumptions that this molecule may be functioning in vivo to regulate the pleiotropic extracellular effects of IL-1 in physiological or pathophysiological processes. Although enticing, these assumptions have not yet been proven to be true. Perhaps we need to look beyond, or within, and consider that IL-1ra and other members of the IL-1 family may have additional roles in normal or abnormal cell growth and development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Interleukin-1 and interleukin-1 antagonism
Dinarello, C. (1991) · Blood · doi:10.1182/blood.v77.8.1627.1627 · Cited by 2,304
Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor
Hannum, C. H., Wilcox, C. J., Arend, W. P., Joslin, F. G., Dripps, D. J., Heimdal, P. L., Armes, L. G., Sommer, A., Eisenberg, S. P., & Thompson, R. C. (1990) · Nature · doi:10.1038/343336a0 · Cited by 1,122
Self-citationEisenberg, S. P., Evans, R. J., Arend, W. P., Verderber, E., Brewer, M. T., Hannum, C. H., & Thompson, R. C. (1990) · Nature · doi:10.1038/343341a0 · Cited by 1,088
Self-citationCytokines and cytokine inhibitors or antagonists in rheumatoid arthritis
Arend, W. P., & Dayer, J. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330302 · Cited by 949
Self-citationInterleukin-1 receptor antagonist reduces mortality from endotoxin shock
Ohlsson, K., Björk, P., Bergenfeldt, M., Hageman, R., & Thompson, R. C. (1990) · Nature · doi:10.1038/348550a0 · Cited by 853
Carter, D. B., Deibel, M. R., Dunn, C. J., Tomich, C.-S. C., Laborde, A. L., Slightom, J. L., Berger, A. E., Bienkowski, M. J., Sun, F. F., McEwan, R. N., et al. (1990) · Nature · doi:10.1038/344633a0 · Cited by 601
Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist.
Arend, W. P., Welgus, H. G., Thompson, R. C., & Eisenberg, S. P. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114622 · Cited by 581
Self-citationDripps, D. J., Brandhuber, B. J., Thompson, R. C., & Eisenberg, S. P. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99230-6 · Cited by 452
A specific receptor antagonist for interleukin 1 prevents Escherichia coli ‐induced shock in rabbits
Wakabayashi, G., Gelfand, J. A., Burke, J. F., Thompson, R. C., & Dinarello, C. A. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.3.1825816 · Cited by 423
Extension of the Life-Span of Human Endothelial Cells by an Interleukin-1αAntisense Oligomer
Maier, J. A. M., Voulalas, P., Roeder, D., & Maciag, T. (1990) · Science · doi:10.1126/science.2218499 · Cited by 397
A urine inhibitor of interleukin 1 activity that blocks ligand binding.
Seckinger, P., Lowenthal, J. W., Williamson, K., Dayer, J. M., & MacDonald, H. R. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.5.1546 · Cited by 345
Cominelli, F., Nast, C. C., Clark, B. D., Schindler, R., Lierena, R., Eysselein, V. E., Thompson, R. C., & Dinarello, C. A. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114799 · Cited by 333
Haskill, S., Martin, G., Van Le, L., Morris, J., Peace, A., Bigler, C. F., Jaffe, G. J., Hammerberg, C., Sporn, S. A., & Fong, S. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.9.3681 · Cited by 328
Arend, W. P., Joslin, F. G., & Massoni, R. J. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.134.6.3868 · Cited by 322
Self-citationAlexander, H. R., Doherty, G. M., Buresh, C. M., Venzon, D. J., & Norton, J. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.4.1029 · Cited by 295
McIntyre, K. W., Stepan, G. J., Kolinsky, K. D., Benjamin, W. R., Plocinski, J. M., Kaffka, K. L., Campen, C. A., Chizzonite, R. A., & Kilian, P. L. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.4.931 · Cited by 289
Granowitz, E. V., Clark, B. D., Mancilla, J., & Dinarello, C. A. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98655-2 · Cited by 267
Eisenberg, S. P., Brewer, M. T., Verderber, E., Heimdal, P., Brandhuber, B. J., & Thompson, R. C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.12.5232 · Cited by 240
IL-1 receptor antagonist and IL-1 beta production in human monocytes are regulated differently
Arend, W. P., Smith, M. F., Janson, R. W., & Joslin, F. G. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.5.1530 · Cited by 215
Self-citationAn IL-1 inhibitor from human monocytes. Production and characterization of biologic properties.
Arend, W. P., Joslin, F. G., Thompson, R. C., & Hannum, C. H. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.6.1851 · Cited by 206
Self-citationBalavoine, J. F., de Rochemonteix, B., Williamson, K., Seckinger, P., Cruchaud, A., & Dayer, J. M. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112669 · Cited by 205
Poutsiaka, D., Clark, B., Vannier, E., & Dinarello, C. (1991) · Blood · doi:10.1182/blood.v78.5.1275.1275 · Cited by 199
Induction of the interleukin 1 receptor antagonist protein by transforming growth factor‐β
Turner, M., Chantry, D., Katsikis, P., Berge, A., Brennan, F. M., & Feldmann, M. (1991) · European Journal of Immunology · doi:10.1002/eji.1830210708 · Cited by 163
Native interleukin 1 inhibitors
Larrick, J. W. (1989) · Immunology Today · doi:10.1016/0167-5699(89)90308-3 · Cited by 163
Ulich, T. R., Yin, S., Guo, K., del Castillo, J. M. G., Eisenberg, S. P., & Thompson, R. C. (1991) · PubMed Central · Cited by 157
Seckinger, P., Klein‐Nulend, J., Alander, C., Thompson, R. C., Dayer, J. M., & Raisz, L. G. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.12.4181 · Cited by 154
Interleukin 1-receptor antagonist blocks interleukin 1-induced sleep and fever
Opp, M. R., & Krueger, J. M. (1991) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1991.260.2.r453 · Cited by 152
Chang, T. L., Shea, C. M., Urioste, S. S., et al. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.9.2803 · Cited by 143
Seckinger, P., Williamson, K., Balavoine, J.-F., Mach, B., Mazzei, G. J., SHAW, A. R., & Dayer, J. M. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.5.1541 · Cited by 140
Prieur, A., Griscelli, C., Kaufmann, M., & Dayer, J. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91854-x · Cited by 122
Henderson, B. E., Thompson, R. C., Hardingham, T., & Lewthwaite, J. (1991) · Cytokine · doi:10.1016/1043-4666(91)90023-7 · Cited by 114
Smith, R. J., Chin, J. E., Sam, L. M., & Justen, J. M. (1991) · Arthritis & Rheumatism · doi:10.1002/art.1780340112 · Cited by 113
Henricson, B. E., Neta, R., & Vogel, S. N. (1991) · Infection and Immunity · doi:10.1128/iai.59.3.1188-1191.1991 · Cited by 91
Roux-Lombard, P., Modoux, C., & Dayer, J. (1989) · Cytokine · doi:10.1016/1043-4666(89)91047-8 · Cited by 87
Purification and characterization of a 26‐kDa competitive inhibitor of interleukin 1
Mazzei, G. J., Seckinger, P., Dayer, J., & SHAW, A. R. (1990) · European Journal of Immunology · doi:10.1002/eji.1830200332 · Cited by 74
A point mutation uncouples human interleukin-1 beta biological activity and receptor binding.
Gehrke, L., Jobling, S. A., Paik, L. S., McDonald, B., Rosenwasser, L. J., & Auron, P. E. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)39265-8 · Cited by 71
Conversion of the interleukin 1 receptor antagonist into an agonist by site-specific mutagenesis.
Ju, G., Labriola–Tompkins, E., Campen, C. A., Benjamin, W. R., Karas, J. L., Plocinski, J. M., Biondi, D., Kaffka, K. L., Kilian, P. L., & Eisenberg, S. P. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.7.2658 · Cited by 69
Dayer-Métroz, M.-D., Wollheim, C. B., Seckinger, P., & Dayer, J. (1989) · Journal of Autoimmunity · doi:10.1016/0896-8411(89)90152-2 · Cited by 55
Zahedi, K. A., Seldin, M. F., Rits, M., Ezekowitz, R. A. B., & Whitehead, A. S. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.146.12.4228 · Cited by 47
Spinas, G. A., Bloesch, D., Kaufmann, M., Keller, U. B., & Dayer, J. (1990) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1990.259.5.r993 · Cited by 45
Malyak, M., Joslin, F. G., Verderber, E. L., Eisenberg, S. P., & Arend, W. P. (1991) · Journal of Immunological Methods · doi:10.1016/0022-1759(91)90381-o · Cited by 38
Self-citationHuman monocytes produce IL-1 and an inhibitor of IL-1 in response to two different signals
Schur, P. H., Chang, D., Baptiste, P., Uhteg, L. C., & Hanson, D. C. (1990) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(90)90021-h · Cited by 28
Bienkowski, M. J., Eessalu, T. E., Berger, A. E., TRUESDELL, S. E., Shelly, J. A., LABORDE, A. L., Zürcher-Neely, H. A., Reardon, I. M., Heinrikson, R. L., & Chosay, J. G. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)77331-6 · Cited by 25
Mazzei, G. J., Bernasconi, L., Lewis, C., Mermod, J. J., Kindler, V., & SHAW, A. R. (1990) · The Journal of Immunology · doi:10.4049/jimmunol.145.2.585 · Cited by 24
Shields, J. G., Bernasconi, L., Benotto, W., SHAW, A. R., & Mazzei, G. J. (1990) · Cytokine · doi:10.1016/1043-4666(90)90006-f · Cited by 9
Cited by
Multiple Organ Failure Pathophysiology and Potential Future Therapy
DEITCH, E. A. (1992) · Annals of Surgery · doi:10.1097/00000658-199208000-00002 · Cited by 1,380
The Tumor Necrosis Factor Ligand and Receptor Families
Bazzoni, F., & Beutler, B. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606273342607 · Cited by 1,225
INTERLEUKIN-1 RECEPTOR ANTAGONIST: Role in Biology
Arend, W. P., Malyak, M., Guthridge, C. J., & Gabay, C. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.27 · Cited by 1,071
Self-citationOrtiz, L. A., DuTreil, M., Fattman, C., Pandey, A. C., Torres, G., Go, K., & Phinney, D. G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704421104 · Cited by 1,019
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
Bresnihan, B., Alvaro-Gracia, J. M., Cobby, M., Doherty, M., Domljan, Z., Emery, P., Nuki, G., Pavelka, K., Rau, R., Rozman, B., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199812)41:12<2196::aid-art15>3.0.co;2-2 · Cited by 981
Metadata
- Authors
- Arend, W. P.
- Venue
- Journal of Clinical Investigation
- Published
- 1991-11-01
- Volume
- 88
- Issue
- 5
- Pages
- 1445-1451
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2129195110
- Cited by
- 595
- References
- 45
- FWCI
- 22.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.